Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | TSPO | P30536 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | HPD | P32754 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355575 | 1.00 | GRM5 (1.00) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608787 | 0.90 | GRM5 (0.81) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608300 | 0.87 | GRM5 (0.77) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607815 | 0.87 | GRM5 (0.77) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609908 | 0.87 | GRM5 (0.77) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608631 | 0.86 | GRM5 (0.75) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609274 | 0.86 | GRM5 (0.75) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609825 | 0.86 | GRM5 (0.75) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607850 | 0.86 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| Basimglurant SCHEMBL560590 | 0.85 | GRM5 (1.00) | GRM5KCNH2ADRB3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| US-20250360118-A1 | TREATMENT OF FIBROTIC DISORDERS WITH METABOTROPIC GLUTAMATE RECEPTOR 5 ANTAGONISTS OR/AND CANNABINOID RECEPTOR 1 ANTAGONISTS | US HEALTH (US) | 2025-11-27 | — | — | US | claimed |
| US-20250257356-A1 | COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF PROTEIN LPA(APO(A)) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-08-14 | — | — | US | claimed |
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | claimed |
| WO-2025124702-A1 | HEAT-SPREADING ELEMENT AND METHOD FOR MANUFACTURING THE SAME | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2025-06-19 | — | — | WO | claimed |
| EP-4539843-A1 | TREATMENT OF FIBROTIC DISORDERS WITH METABOTROPIC GLUTAMATE RECEPTOR 5 ANTAGONISTS OR/AND CANNABINOID RECEPTOR 1 ANTAGONISTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-04-23 | — | — | EP | claimed |
| CN-119677515-A | Treatment of fibrotic diseases using metabotropic glutamate receptor 5 antagonists or/and cannabinoid receptor 1 antagonists | 美国政府健康及人类服务部 | 2025-03-21 | — | — | CN | claimed |
| EP-4471144-A1 | COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF PROTEIN LPA(APO(A)) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2024-12-04 | — | — | EP | claimed |
| CN-118679259-A | Compositions and methods for inhibiting expression of LPA (Apo (a)) proteins | 上海舶望制药有限公司 | 2024-09-20 | — | — | CN | claimed |
| WO-2024088712-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2024-05-02 | — | — | WO | claimed |
| US-20120039999-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | CHATTERJI ASHISH (US) | 2012-02-16 | — | — | US | claimed |
| US-20120040008-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | CHATTERJI ASHISH (US) | 2012-02-16 | — | — | US | claimed |
| JP-4690395-B2 | — | — | 2011-06-01 | — | — | JP | claimed |
| US-20100048569-A1 | DIAZOLE DERIVATIVES | BUETTELMANN BERND | 2010-02-25 | — | — | US | claimed |
| US-20090054490-A1 | METHODS FOR THE TREATMENT OF GERD WITH MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | US | claimed |
| WO-2009024491-A1 | USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GERD | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | claimed |
| EP-1756086-B1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | claimed |
| EP-1756086-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | claimed |
| US-20060030559-A1 | Diazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | claimed |
| WO-2005118568-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048569-A1 | DIAZOLE DERIVATIVES | GRM1, GRM2, GRIN2B | GRM5 14/4885KCNH2 551/4885ADRB3 1151/4885 |
| US-20060030559-A1 | Diazole derivatives | GRM1, GRM2, GRIN2B | GRM5 14/4885KCNH2 551/4885ADRB3 1151/4885 |
| US-20120040008-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
| US-20250257356-A1 | COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF PROTEIN LPA(APO(A)) | APOB, LPAR2, LPAR1 | GRM5 4588/4885KCNH2 4495/4885ADRB3 2193/4885 |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | GRM5, OPRL1, GRM1 | GRM5 1/4885KCNH2 2941/4885ADRB3 489/4885 |
| US-20090054490-A1 | METHODS FOR THE TREATMENT OF GERD WITH MGLUR5 ANTAGONISTS | GRM5, HRH2, GRPR | GRM5 1/4885KCNH2 1043/4885ADRB3 533/4885 |
| US-20120039999-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.